Study to Evaluate and Compare Safety and Pharmacokinetics of the HCP1004 and VIMOVO 500/20mg
Not Applicable
Completed
- Conditions
- Diseases of the musculo-skeletal system and connective tissue
- Registration Number
- KCT0000701
- Lead Sponsor
- Hanmi Pharm
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Completed
- Sex
- Male
- Target Recruitment
- 68
Inclusion Criteria
1. BMI: 18.0 - 27.0 kg/m2
2. Willingness to sign the written Informed Consent Form
Exclusion Criteria
1.Evidence of clinically relevant pathology
2.History of relevant drug and food allergies
3.Positive screen on drugs of abuse
4.Participation in a drug study within 3months prior to drug administration.
Study & Design
- Study Type
- Interventional Study
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method AUClast Naproxen and Esomeprazole ;Cmax of Naproxen and Esomeprazole
- Secondary Outcome Measures
Name Time Method Tmax, t1/2, CL/F, AUCinf of Naproxen and Esomeprazole ;t1/2 of Naproxen and Esomeprazole ;CL/F of Naproxen and Esomeprazole ; AUCinf of Naproxen and Esomeprazole